Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris(University of Pittsburgh), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Peter Brossart(University of Bonn), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Fernando Concha‐Benavente(UPMC Hillman Cancer Center), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Jeffery S. Russell(University of Utah), Li Li(Nanjing Medical University), S. Ramkumar(University Hospital Southampton NHS Foundation Trust), J. Guigay(Centre Antoine Lacassagne), Caroline Even(Institut Gustave Roussy), Makoto Tahara(National Cancer Center Hospital East)
Cited by 160
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k